|
Dr. Swindell joined Phyton Biotech in 2004. Prior to Phyton, he was Senior Vice President, Research and Development at Protarga, where he co-invented Protarga's targeted paclitaxel oncology drug, Taxoprexin® and led the R&D team responsible for Taxoprexin's advancement into Phase III clinical evaluation. From 1980 until he joined Protarga in 1999, Dr. Swindell served as Professor on the faculty of Bryn Mawr College in the Department of Chemistry. At Bryn Mawr, he led an internationally recognized and NIH-funded research program focused on the chemistry of paclitaxel, and invented a paclitaxel manufacturing process which was licensed to NaPro BioTherapeutics. He is an inventor on 22 issued patents, has published numerous scholarly articles, and has made more than 100 invited or submitted research presentations. Dr. Swindell received his BS from the University of Houston, Houston, Texas, his Ph.D. from Rice University, Houston, Texas, and carried out postdoctoral research as a Swiss National Science Foundation Postdoctoral Fellow at the ETH-Zürich, Zürich, Switzerland. | 